AI Enters the Pharmacy: Novo Nordisk Partners OpenAI for Drug Discovery
HEALTHCARE & SCIENCE Danish pharmaceutical giant Novo Nordisk announced a sweeping partnership with OpenAI to integrate AI across its entire business — from drug discovery and clinical trials to manufacturing and supply chains. The full deployment is planned by end of 2026. The deal aims to accelerate identification of new obesity and diabetes treatments. CEO Mike Doustdar was explicit: AI would "supercharge" scientists, not replace them — though the company acknowledged AI would curb future hiring growth. Medicine is changing faster than regulation can keep up. AI × HEALTHCARE